Pharming Group N.V (PHARM) | Stock Overview & Key Data
Pharming Group N.V. | Mid-cap | Healthcare
Pharming Group N.V. | Mid-cap | Healthcare
Pharming Group N.V Performance Comparison
Stock Range
Today's Range
Low: €1.22
High: €1.27
on September 23, 2025
52 Week Range
Low: €0.66
High: €1.32
on April 7, 2025
on September 11, 2025
All-Time High: €459.55 on July 10, 2000
Explore how other NL stocks compare to their 52-week ranges: View NL Market 52-Week Insights
Key Statistics
Market Cap
€841.3M
EPS
-0.01
P/E Ratio (TTM)
57.15
Forward P/E
-120.60
P/B Ratio
3.45
PEG Ratio
-120.60
Div. Yield
N/A
ROE
-3.70%
Beta
0.586
Debt to Equity
53.57
Financial Highlights
Profitability
Gross Margin
90.38%
Operating Margin
3.27%
Profit Margin
-2.41%
Returns and Earnings
Return on Assets (TTM)
2.85%
Return on Equity (TTM)
-3.70%
EBITDA
€12.2M
Net Income (TTM)
€-7.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.50
Quarterly Revenue Growth (YoY)
25.80%
Quarterly Earnings Growth (YoY)
7.25%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Pharming Group N.V PHARM | 841.30M Mid-cap | 3.31% | 8.70% | 38.89% | 56.25% | 30.21% | 60.26% | 16.82% | 34.41% |
| Galapagos NV GLPGA | 1.89B Large-cap | 6.36% | 4.05% | 23.22% | 19.63% | 4.73% | 8.94% | -34.52% | -76.29% |
| Vivoryon VVY | 43.48M Small-cap | -0.60% | 15.97% | 11.33% | -15.66% | -20.48% | -28.33% | -81.97% | -65.85% |
| Koninklijke Philips PHIA | 22.73B Large-cap | -0.92% | -1.20% | 22.01% | 0.68% | -2.90% | -19.28% | 48.63% | -40.77% |
| AMG Critical AMG | 914.48M Mid-cap | -4.15% | 6.01% | 49.83% | 60.50% | 88.08% | 55.39% | 15.21% | 92.95% |
| Wereldhave N.V WHA | 844.84M Mid-cap | -1.07% | -2.53% | 9.07% | 18.72% | 31.53% | 22.81% | 57.62% | 125.85% |
Ownership & Short Interest
Insider Ownership
3.55%
Institutional Ownership
14.19%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
15M
Average 90-Day Volume
16M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is PHARM's 52-week high and low?
- In the last 52 weeks, Pharming Group N.V reached a high of €1.32 (on September 11, 2025) and a low of €0.66 (on April 7, 2025).
- What is the market cap and P/E ratio for PHARM?
- Curious about Pharming Group N.V's size and valuation? Its market capitalization stands at 841.30M. When it comes to valuation, the P/E ratio (trailing twelve months) is 57.15, and the forward P/E (looking ahead) is -120.60.
- Does PHARM pay dividends? If so, what's the yield?
- As for dividends, Pharming Group N.V isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Pharming Group N.V's main competitors or similar companies to consider before investing?
When looking at Pharming Group N.V, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Galapagos NV
GLPGA1.89B Healthcare Biotechnology 8.94% -34.52% Vivoryon
VVY43.48M Healthcare Biotechnology -28.33% -81.97% Koninklijke Philips
PHIA22.73B Healthcare Medical Devices -19.28% 48.63% AMG Critical
AMG914.48M Basic Materials Other Industrial Metals & Mining 55.39% 15.21% Wereldhave N.V
WHA844.84M Real Estate REIT - Retail 22.81% 57.62% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Pharming Group N.V.? (e.g., ROE, Debt/Equity)
- To get a sense of Pharming Group N.V's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -3.70%, the Debt to Equity ratio from the most recent quarter is 53.57, and its Gross Profit Margin stands at 90.38%.
- What is the recent revenue and earnings growth for PHARM?
- Looking at Pharming Group N.V's growth, its revenue over the trailing twelve months (TTM) was €290M. Compared to the same quarter last year (YoY), quarterly revenue grew by 25.80%, and quarterly earnings saw a YoY growth of 7.25%.
- How much of PHARM stock is held by insiders and institutions?
- Wondering who owns Pharming Group N.V stock? Company insiders (like executives and directors) hold about 3.55% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 14.19%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.